The effects of anemia in hematologic malignancies: More than a symptom

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 8, 2002, Pages 40-44

  Littlewood, Timothy ^a,b   Mandelli, Franco ^a,b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; BONE MARROW; CELL INFILTRATION; CHRONIC LYMPHATIC LEUKEMIA; CONFERENCE PAPER; DYSPNEA; EXHAUSTION; FATIGUE; HEADACHE; HEMATOLOGIC DISEASE; HEMOLYSIS; HUMAN; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NUTRITIONAL DEFICIENCY; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL; VERTIGO;

EID: 0036298226     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(02)70173-5     Document Type: Conference Paper

References (42)

1. Neoplasia and the erythron
2. Reporting results of cancer treatment
3. Chemotherapy-induced anemia in adults: Incidence and treatment
4. Biological basis of anemia
5. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors
6. Multiple myeloma: Review of 869 cases
7. A new staging system for multiple myeloma based on the number of S-phase plasma cells
8. Maintenance therapy and supportive care for patients with multiple myeloma
9. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: A prospective study
10. r-HuErythropoietin treatment increases efficacy of neoadjuvant radiochemotherapy and improves cancer free survival of patients with oral squamous cell carcinoma: A 17 month follow up
11. Prognostic value of hemoglobin concentrations in patients with advanced head and neck cancer treated with combined radio-chemotherapy and surgery
12. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: Results of a retrospective study of 386 patients
13. Significance of hemoglobin concentrations for treatment outcome
14. The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma
15. Erythropoietin treatment of anemia associated with multiple myeloma
16. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma
17. Recombinant human erythropoietin in the anaemia of multiple myeloma and non-Hodgkin's lymphoma
18. Anemia associated with non-platinum chemotherapy (CT) for Hodgkin's lymphoma (HL) or non-Hodgkin's lymphoma (NHL)
19. Erythropoietin for anaemia in cancer patients
20. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP
21. Cisplatin-associated anemia: An erythropoietin deficiency syndrome
22. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice
23. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study
24. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life similar to three-times-weekly dosing
25. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, doubleblind, placebo-controlled trial
26. Reduced transfusion, increased hemoglobin, and improved QOL for epoetin alfa-treated patients receiving nonplatinum chemotherapy for hematologic malignancies
27. Efficacy of a once-weekly dosage regimen of epoetin alfa in hematologic malignancies
28. Functional status and quality-of-life benefits of epoetin alfa independent of disease response in the treatment of patients with haematological malignancies
29. Update on the role of epoetin alfa in hematologic malignancies and myelodysplastic syndromes
30. Serum erythropoietin in chronic lymphocytic leukaemia
31. Chronic lymphocytic leukemia
32. Clinical staging of chronic lymphocytic leukemia
33. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis
34. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia
35. Myelodysplastic syndrome
36. Serum erythropoietin concentrations in patients with myelodysplastic syndromes
37. Measurement of serum cytokine levels in patients with myelodysplastic syndromes
38. Efficacy of erythropoietin in the myelodysplastic syndromes: A meta-analysis of 205 patients from 17 studies
39. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin
40. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes
41. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin. Evidence for in vivo synergy
42. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin